Brexit - the EU FMD's painful problem7 Feb 2019
Teething problems are no stranger to the implementation of new regulations, but with the EU FMD, Brexit came like a set of wisdom teeth – late, painful and problematic.
Now, after 5 years of preparation and with the compliance deadline only weeks away, the lack of clarity around Brexit remains an obstacle for pharma companies operating on both sides of the Channel.
So, what does Brexit mean for the FMD?
We ask industry leader - Daniel Tedham, Managing Director, Wasdell Manufacturing a division of the Wasdell Group - about the current state of the exit agreement, the possibility and problems of a ‘no deal’ and the impact on the UK and European pharmaceutical industries.
What will be the impact of Brexit on the FMD?
Tedham: “There is still a lot of uncertainty surrounding the impact that Brexit will have on the EU FMD regulations. The date for the UK’s exit from the EU is the 29 March 2019, meaning up until this date the UK will legally need to comply with all EU legislation including the EU FMD.
“The Medicines and Healthcare products Regulatory Agency (MHRA) has recently released guidance which outlines an implementation period between 30 March 2019 and 31 December 2020, during which time the UK pharmaceutical industry would continue to meet all EU FMD requirements while the UK authorities work to develop a system that will work alongside the EU’s.”
What are the implications of a ‘no-deal’ Brexit?
Tedham: “While the UK will still have its own Medicines Verification Systems – the UKMVS – it would also need continued access to the European Medicines Verification System (EMVS) to allow the FMD legislation to be fully effective. In the event of a ‘no-deal’ Brexit this is not guaranteed.
“The logistics of how this will work are not yet fully understood. The political fallout of a hard Brexit could potentially affect patient safety due to reduced access to vital medicines and delays in accessing critical information.”
What are companies doing to ensure operations are unaffected by Brexit?
Tedham: “Many UK-based companies have opted to create contingency plans, establishing a presence in the EU or forming partnerships with third parties to ensure sufficient resource for additional release testing requirements. At Wasdell, we are building a new facility in Dundalk, Ireland to ensure business continuity for our customers. We have also started to develop bespoke alterations to supply chains to ensure minimal impact, regardless of the outcome of Brexit negotiations.”
How real-world data can revolutionise drug development
9 Aug 2019
Utilising the current data environment and its data pools for the benefit of advancing research.Read more
Colorcon to incorporate TruTag's edible 'optical barcodes' in tablet film coatings
6 Aug 2019
The benefits of this innovation include the ability to instantly and unequivocally authenticate products when suspect events.Read more
Mylan and Pfizer create new global pharma company
29 Jul 2019
The transaction will allow the new company to expand the geographic reach of Mylan's existing broad product portfolio and future pipeline.Read more
GSK opens new continuous manufacturing facilities in Singapore
11 Jul 2019
Opening of continuous manufacturing facilities and expansion of production building will boost capabilities to accelerate the supply of new breakthrough medicines to patients globally.Read more
Catalent extends global commercial spray drying capabilities in Europe
9 Jul 2019
Company's customers to have immediate access to Niro PSD2 and PSD4 spray driers, which are supported by dedicated clean area facilities for both solvent and aqueous processing of potent or non-potent drug formulations.Read more
Inaugural Bio Integrates conference highlights industry's inefficiency in developing products
18 Jun 2019
Industry leaders give voice to issues and trends shaping the biotech sector, including the importance of collaboration.Read more
Lessons learned from early EU FMD adopters
13 May 2019
Data exchange, investment costs, resources and hardware identified as some of the biggest challenges.Read more
Brexit's trick or treat on patient safety
29 Apr 2019
Despite a delayed Brexit, unpredictability adds further complications to the EU FMD regulation.Read more
Surge of Indian biosimilars market forecast in 2019
22 Apr 2019
India predicted to be one of the world’s ‘fastest growing bio’ hubs in 2019, fuelled by new biosimilars production.Read more
RAPS on delayed Brexit
26 Mar 2019
The post-Brexit regulatory environment continues to weigh heavily on the minds of regulatory professionals.Read more
Are you a supplier
Here's what we can do for you
- Generate quality leads for your business
- Stay visible for 365 days of the year
- Receive product inquiries and respond to meeting requests directly
- Improve company online presence through Search Engine Optimisation